ARTICLE | Company News
BioMarin sales and marketing update
December 21, 2015 8:00 AM UTC
The Highly Specialised Technologies (HST) Evaluation Committee of the U.K.’s NICE issued a final draft guidance provisionally recommending Vimizim elosulfase alfa to treat mucopolysaccharidosis IVA (...